Sichuan Shuangma (000935): Pharmaceutical technology+PE dual-core drive high performance growth
Sichuan Shuangma (000935): Acquisition progress exceeds expectations, the company opens a new growth pole
Sichuan Shuangma (000935): Negative investment is dragging down performance, acquisition of asset layout, pharmaceuticals
Sichuan Shuangma (000935): Asset acquisition layout favors biomedical performance growth
Sichuan Shuangma (000935): Overfunding of new products will continue to expand the scale of management, and self-investment may be under pressure
Sichuan Shuangma (000935): Performance rewards helped 23 years of growth, investment losses dragged down Q1 performance
Sichuan Shuangma (000935): Indirect shareholders switched to direct shareholding to benefit the company's development
Sichuan Shuangma (000935): Performance is in line with expectations, optimistic about future growth
Sichuan Shuangma (000935): The size of the second phase fund exceeds expectations and is optimistic about the release of the company's performance
Sichuan Shuangma (000935): Equity investment welcomes favorable policies and is optimistic about future performance growth
Sichuan Shuangma (000935): The new fund raised more than expected repurchases fully demonstrated the company's confidence
Sichuan Shuangma (000935): Declining investment, performance under pressure, waiting for performance to be released
Sichuan Shuangma (000935): Company repurchases show confidence and optimism for long-term growth
Sichuan Shuangma (000935): Investment income drags down performance in the short term and is expected to contribute to profit growth in the long term
Sichuan Shuangma (000935): Investment declines, performance is under pressure, optimistic about future performance release
Sichuan Shuangma (000935): New products are expected to raise investment income/performance rewards within the year or accelerate release within the year
Sichuan Shuangma (000935): CARRY may gradually release growth potential or may be due to the withdrawal return of managed funds and the landing of new funds
Sichuan Shuangma (000935): Core Benefit Targets for the Venture Capital Industry under the Comprehensive Registration System
Sichuan Shuangma (000935): The listing process of important investment projects Guriwatt and Honeycomb Energy further accelerates performance release
Sichuan Shuangma (000935): The Harmonious Green Industry Fund will make every effort to incubate the pillars of Chinese manufacturing enterprises